Nephrogenic systemic fibrosis and gadolinium-containing radiological contrast agents: An update

Clinical Pharmacology and Therapeutics

Volumn 89, Issue 6, 2011, Pages 920-923

  Jalandhara, N ^a,b   Arora, R ^a,b   Batuman, V ^a,b  

^a TULANE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b Southeast Louisiana Veterans Healthcare Center (SLVHC)   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

GADOBENATE DIMEGLUMINE; GADOBUTROL; GADODIAMIDE; GADOLINIUM; GADOLINIUM PENTETATE; GADOTERATE MEGLUMINE; GADOTERIDOL; GADOVERSETAMIDE; RAPAMYCIN; UNCLASSIFIED DRUG; VASOCIST;

ARTICLE; CLINICAL FEATURE; HUMAN; HUMAN TISSUE; KIDNEY TRANSPLANTATION; MAJOR CLINICAL STUDY; NEPHROGENIC SYSTEMIC FIBROSIS; NUCLEAR MAGNETIC RESONANCE IMAGING; PATHOGENESIS; PLASMAPHERESIS; PRIORITY JOURNAL;

ANIMALS; CONTRAST MEDIA; GADOLINIUM; GLOMERULAR FILTRATION RATE; HUMANS; NEPHROGENIC FIBROSING DERMOPATHY;

EID: 79956327633     PISSN: 00099236     EISSN: 15326535     Source Type: Journal    
DOI: 10.1038/clpt.2010.346     Document Type: Article

References (31)

1. Cowper, S.E., Robin, H.S., Steinberg, S.M., Su, L.D., Gupta, S. & LeBoit, P.E. Scleromyxoedema-like cutaneous diseases in renal-dialysis patients. Lancet 356, 1000-1001 (2000).
2. Grobner, T. Gadolinium-a specifc trigger for the development of nephrogenic fbrosing dermopathy and nephrogenic systemic fbrosis? Nephrol. Dial. Transplant. 21, 1104-1108 (2006).
3. Marckmann, P. et al. Nephrogenic systemic fbrosis: suspected causative role of gadodiamide used for contrast-enhanced magnetic resonance imaging. J. Am. Soc. Nephrol. 17, 2359-2362 (2006). (Pubitemid 44300951)
4. Swartz, R.D., Croford, L.J., Phan, S.H., Ike, R.W. & Su, L.D. Nephrogenic fbrosing dermopathy: a novel cutaneous fbrosing disorder in patients with renal failure. Am. J. Med. 114, 563-572 (2003). (Pubitemid 36577259)
5. Jan, F., Segal, J.M., Dyer, J., LeBoit, P., Siegfried, E. & Frieden, I.J. Nephrogenic fbrosing dermopathy: two pediatric cases. J. Pediatr. 143, 678-681 (2003). (Pubitemid 37452802)
6. Heinz-Peer, G. et al. Prevalence of NSF following intravenous gadolinium-contrast media administration in dialysis patients with endstage renal disease. Eur. J. Radiol. 76, 129-134 (2010).
7. Prince, M.R. et al. Incidence of nephrogenic systemic fbrosis at two large medical centers. Radiology 248, 807-816 (2008).
8. Cowper, S.E. Nephrogenic Fibrosing Dermopathy, 2001-2009. (2010).
9. Chrysochou, C., Buckley, D.L., Dark, P., Cowie, A. & Kalra, P.A. Gadolinium-enhanced magnetic resonance imaging for renovascular disease and nephrogenic systemic fbrosis: critical review of the literature and UK experience. J. Magn. Reson. Imaging 29, 887-894 (2009).
10. Moschella, S.L., Kay, J., Mackool, B.T. & Liu, V. Case records of the Massachusetts General Hospital. Weekly clinicopathological exercises. Case 35-2004.
11. A 68-year-old man with end-stage renal disease and thickening of the skin. N. Engl. J. Med. 351, 2219-2227 (2004).
12. Swaminathan, S. et al. Cardiac and vascular metal deposition with high mortality in nephrogenic systemic fbrosis. Kidney Int. 73, 1413-1418 (2008). (Pubitemid 351770496)
13. Kucher, C., Steere, J., Elenitsas, R., Siegel, D.L. & Xu, X. Nephrogenic fbrosing dermopathy/nephrogenic systemic fbrosis with diaphragmatic involvement in a patient with respiratory failure. J. Am. Acad. Dermatol. 54, S31-S34 (2006). (Pubitemid 43113084)
14. Collidge, T.A. et al. Gadolinium-enhanced MR imaging and nephrogenic systemic fbrosis: retrospective study of a renal replacement therapy cohort. Radiology 245, 168-175 (2007). (Pubitemid 47417800)
15. Wahba, I.M., Simpson, E.L. & White, K. Gadolinium is not the only trigger for nephrogenic systemic fbrosis: insights from two cases and review of the recent literature. Am. J. Transplant. 7, 2425-2432 (2007). (Pubitemid 47347864)
16. Jofe, P., Thomsen, H.S. & Meusel, M. Pharmacokinetics of gadodiamide injection in patients with severe renal insufciency and patients undergoing hemodialysis or continuous ambulatory peritoneal dialysis. Acad. Radiol. 5, 491-502 (1998). (Pubitemid 28303906)
17. Swan, S.K. et al. Safety and pharmacokinetic profle of gadobenate dimeglumine in subjects with renal impairment. Invest. Radiol. 34, 443-448 (1999). (Pubitemid 29302836)
18. Khurana, A., Runge, V.M., Narayanan, M., Greene, J.F. Jr & Nickel, A.E. Nephrogenic systemic fbrosis: a review of 6 cases temporally related to gadodiamide injection (omniscan). Invest. Radiol. 42, 139-145 (2007). (Pubitemid 46104895)
19. Frenzel, T., Lengsfeld, P., Schirmer, H., Hütter, J. & Weinmann, H.J. Stability of gadolinium-based magnetic resonance imaging contrast agents in human serum at 37 degrees C. Invest. Radiol. 43, 817-828 (2008).
20. VanWagoner, M., O'Toole, M., Worah, D., Leese, P.T. & Quay, S.C. A phase I clinical trial with gadodiamide injection, A nonionic magnetic resonance imaging enhancement agent. Invest. Radiol. 26, 980-986 (1991).
21. Varani, J. et al. Efects of gadolinium-based magnetic resonance imaging contrast agents on human skin in organ culture and human skin fbroblasts. Invest. Radiol. 44, 74-81 (2009).
22. Steger-Hartmann, T., Raschke, M., Riefke, B., Pietsch, H., Sieber, M.A. & Walter, J. The involvement of pro-infammatory cytokines in nephrogenic systemic fbrosis - a mechanistic hypothesis based on preclinical results from a rat model treated with gadodiamide. Exp. Toxicol. Pathol. 61, 537-552 (2009).
23. Quan, T.E., Cowper, S.E. & Bucala, R. The role of circulating fbrocytes in fbrosis. Curr. Rheumatol. Rep. 8, 145-150 (2006).
24. Gibson, S.E., Farver, C.F. & Prayson, R.A. Multiorgan involvement in nephrogenic fbrosing dermopathy: an autopsy case and review of the literature. Arch. Pathol. Lab. Med. 130, 209-212 (2006). (Pubitemid 43237993)
25. Morcos, S.K. Nephrogenic systemic fbrosis following the administration of extracellular gadolinium based contrast agents: is the stability of the contrast agent molecule an important factor in the pathogenesis of this condition? Br. J. Radiol. 80, 73-76 (2007). (Pubitemid 46951248)
26. Grant, D., Johnsen, H., Juelsrud, A. & Løvhaug, D. Efects of gadolinium contrast agents in naïve and nephrectomized rats: relevance to nephrogenic systemic fbrosis. Acta Radiol. 50, 156-169 (2009).
27. Chrysochou, C. et al. Low risk for nephrogenic systemic fbrosis in nondialysis patients who have chronic kidney disease and are investigated with gadolinium-enhanced magnetic resonance imaging. Clin. J. Am. Soc. Nephrol. 5, 484-489 (2010).
28. Baron, P.W. et al. Nephrogenic fbrosing dermopathy after liver transplantation successfully treated with plasmapheresis. Am. J. Dermatopathol. 25, 204-209 (2003). (Pubitemid 36706461)
29. Swaminathan, S. et al. Rapid improvement of nephrogenic systemic fbrosis with rapamycin therapy: possible role of phospho-70-ribosomal-S6 kinase. J. Am. Acad. Dermatol. 62, 343-345 (2010).
30. Gilliet, M., Cozzio, A., Burg, G. & Nestle, F.O. Successful treatment of three cases of nephrogenic fbrosing dermopathy with extracorporeal photopheresis. Br. J. Dermatol. 152, 531-536 (2005). (Pubitemid 40547128)
31. Kim, K.H., Fonda, J.R., Lawler, E.V., Gagnon, D. & Kaufman, J.S. Change in use of gadolinium-enhanced magnetic resonance studies in kidney disease patients after US Food and Drug Administration warnings: a cross-sectional study of Veterans Afairs Health Care System data from 2005-2008. Am. J. Kidney Dis. 56, 458-467 (2010).